SLC5A2 and Hepatic fibrosis: The use of the sodium-glucose cotransporter-2 (SGLT2) inhibitors and incretin treatments, including oral inhibitors of dipeptidylpeptidase-4 (DPP-4) and injectable glucagon-like peptide-1 (GLP-1) receptor agonists, ameliorated diabetic conditions and reduced liver fibrosis and inflammation [60].